Drugging the undruggable RAS: Mission Possible?
Open accessThe DOI matches its Crossref record; 231 of the 231 references it cites were found in a registry or an index.
Abstract
Despite more than three decades of intensive effort, no effective pharmacological inhibitors of the RAS oncoproteins have reached the clinic, prompting the widely held perception that RAS proteins are 'undruggable'. However, recent data from the laboratory and the clinic have renewed our hope for the development of RAS-inhibitory molecules. In this Review, we summarize the progress and the promise of five key approaches. Firstly, we focus on the prospects of using direct inhibitors of RAS. Secondly, we address the issue of whether blocking RAS membrane association is a viable approach. Thirdly, we assess the status of targeting RAS downstream effector signalling, which is arguably the most favourable current approach. Fourthly, we address whether the search for synthetic lethal interactors of mutant RAS still holds promise. Finally, RAS-mediated changes in cell metabolism have recently been described and we discuss whether these changes could be exploited for new therapeutic directions. We conclude with perspectives on how additional complexities, which are not yet fully understood, may affect each of these approaches.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“KRAS has historically been considered ‘undruggable’ owing to a lack of pharmacologically targetable pockets within the mutant isoforms.”
From The current state of the art and future trends in RAS-targeted cancer therapies (2022) · cites this paper as [25]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Genetic analysis has shown that 98% of RAS mutations that cause cancer are concentrated in three residues: G12, G13, and Q61.”
From The Role of KRAS Mutations in Colorectal Cancer: Biological Insights, Clinical Implications, and Future Therapeutic Perspectives (2025) · cites this paper as [16]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“A number of highly selective and potent inhibitors have been developed against kinases in the Ras signaling network particularly those in the MAPK and PI3K/mTOR pathways (9, 12).”
From KRAS mutation in pancreatic cancer (2021) · cites this paper as [9]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“For more than 40 years, KRAS mutation has been considered “undruggable” [16, 17].”
From Targeting KRAS mutant cancers: from druggable therapy to drug resistance (2022) · cites this paper as [16]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“For many proteins known to be involved in driving diseases, such as KRAS in many cancers, conventional drug development strategies often aimed at developing inhibitors have failed [118, 119].”
From Advances in targeted degradation of endogenous proteins (2019) · cites this paper as [119]
Experimental — accuracy not yet measured
17 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590
Hanahan, D., & Weinberg, R. A. (2000) · Cell · doi:10.1016/s0092-8674(00)81683-9 · Cited by 29,219
Understanding the Warburg Effect: The Metabolic Requirements of Cell Proliferation
Vander Heiden, M. G., Cantley, L. C., & Thompson, C. B. (2009) · Science · doi:10.1126/science.1160809 · Cited by 16,197
Genome engineering using the CRISPR-Cas9 system
Ran, F. A., Hsu, P. D., Wright, J., Agarwala, V., Scott, D. A., & Zhang, F. (2013) · Nature Protocols · doi:10.1038/nprot.2013.143 · Cited by 11,133
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity
Barretina, J., Caponigro, G., Stransky, N., Venkatesan, K., Margolin, A. A., Kim, S., Wilson, C. J., Lehár, J., Kryukov, G. V., Sonkin, D., et al. (2012) · Nature · doi:10.1038/nature11003 · Cited by 7,950
Vogelstein, B., Papadopoulos, N., Velculescu, V. E., Zhou, S., Diaz, L. A., & Kinzler, K. W. (2013) · Science · doi:10.1126/science.1235122 · Cited by 7,863
Genome-scale CRISPR-Cas9 knockout screening in human cells
Shalem, O., Sanjana, N. E., Hartenian, E., Shi, X., Scott, D. A., Mikkelsen, T. S., Heckl, D., Ebert, B. L., Root, D. E., Doench, J. G., et al. (2014) · Science · doi:10.1126/science.1247005 · Cited by 5,234
Wilhelm, S. M., Carter, C., Tang, L., Wilkie, D., McNabola, A., Rong, H., Chen, C., Zhang, X., Vincent, P., McHugh, M., et al. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-1443 · Cited by 4,017
Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1
Barbie, D. A., Tamayo, P., Boehm, J. S., Kim, S. Y., Moody, S. E., Dunn, I. F., Schinzel, A. C., Sandy, P., Meylan, E., Scholl, C., et al. (2009) · Nature · doi:10.1038/nature08460 · Cited by 3,890
Aerobic glycolysis: Meeting the metabolic requirements of cell proliferation
Lunt, S. Y., & Vander Heiden, M. G. (2011) · Annual Review of Cell and Developmental Biology · doi:10.1146/annurev-cellbio-092910-154237 · Cited by 3,057
Research works printed but not linked: 1
- Kumar, M. S. et al. The GATA2 transcriptional network is requisite for RAS oncogene-driven non-small cell lung cancer. Cell 149, 642–655 (2012). · DOI · Paper page
Cited by
Items 901–1,000 of 1,007
Ras Signaling in Breast Cancer
Moon, A. (2021) · Advances in experimental medicine and biology · doi:10.1007/978-981-32-9620-6_4 · Cited by 25
Effects of ivacaftor on systemic inflammation and the plasma proteome in people with CF and G551D
Hoppe, J. E., Wagner, B. D., Harris, J. K., Rowe, S. M., Heltshe, S. L., DeBoer, E. M., & Sagel, S. D. (2022) · Journal of Cystic Fibrosis · doi:10.1016/j.jcf.2022.03.012 · Cited by 21
Discovery of novel Quinazoline-based KRAS G12C inhibitors as potential anticancer agents
Li, L., Zhao, H., Peng, X., Liu, J., Mai, R., Chen, J., Lin, L., Chen, T., Yan, J., Shi, J., et al. (2022) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2022.116962 · Cited by 19
Addressing the Right Targets in Oncology: Challenges and Alternative Approaches
Stock, J. K., Jones, N. P., Hammonds, T. R., Roffey, J., & Dillon, C. (2015) · SLAS DISCOVERY · doi:10.1177/1087057114564349 · Cited by 21
“The family of RAS GTPases, particularly KRAS, have activating mutations not only in NSCLC but also in ~20% of all human cancers, including in approximately 90% of pancreatic cancers.(33,36) Mutant RAS proteins are very well-validated targets, with exceptionally strong linkage to disease pathology, but they have histor…”
BackgroundDevelopment of a Nucleotide Exchange Inhibitor That Impairs Ras Oncogenic Signaling
Marín‐Ramos, N. I., Piñar, C., Vázquez‐Villa, H., Martín‐Fontecha, M., González, Á., Canales, Á., Algar, S., Mayo, P. P., Jiménez‐Barbero, J., Gajate, C., et al. (2016) · Chemistry - A European Journal · doi:10.1002/chem.201604905 · Cited by 19
Targeting Ras signaling in AML: RALB is a small GTPase with big potential
Pomeroy, E. J., & Eckfeldt, C. E. (2017) · Small GTPases · doi:10.1080/21541248.2017.1339765 · Cited by 21
“Transcriptome-scale loss of function screens have identified genes and pathways that exhibit synthetic lethality with mutant Ras.35 For example, a recent CRISPR/Cas9based screen identified synthetic lethal interactions between genes involved in Ras processing and MAPK signaling and oncogenic RAS mutations in human and…”
BackgroundInfluentialChen, Y., Xu, W., Jin, H., Zhang, M., Liu, S., Liu, Y., & Zhang, H. (2024) · ACS Nano · doi:10.1021/acsnano.4c08083 · Cited by 21
Allostery in Disease: Anticancer Drugs, Pockets, and the Tumor Heterogeneity Challenge
Nussinov, R., Yavuz, B. R., & Jang, H. (2025) · Journal of Molecular Biology · doi:10.1016/j.jmb.2025.169050 · Cited by 22
Pavel, M. E., & Sers, C. (2016) · Endocrine Related Cancer · doi:10.1530/erc-16-0370 · Cited by 19
RAL GTPases mediate multiple myeloma cell survival and are activated independently of oncogenic RAS
Seibold, M., Stühmer, T., Kremer, N., Mottok, A., Scholz, C. J., Schlösser, A., Leich, E., Holzgrabe, U., Brünnert, D., Barrio, S., et al. (2019) · Haematologica · doi:10.3324/haematol.2019.223024 · Cited by 21
Tisi, R., Gaponenko, V., Vanoni, M., & Sacco, E. (2020) · Biomolecules · doi:10.3390/biom10111535 · Cited by 19
Lopes, E. C., Dias, M. H., da Silva, M. S., Zeidler, J. D., Vessoni, A. T., Reis, M. S., Boccardo, E., & Armelin, H. A. (2021) · Cell Death and Disease · doi:10.1038/s41419-021-03476-3 · Cited by 16
Kurosaki, H., Nakatake, M., Sakamoto, T., Kuwano, N., Yamane, M., Ishii, K., Fujiwara, Y., & Nakamura, T. (2021) · Cells · doi:10.3390/cells10050985 · Cited by 18
Autophagy-mediated negative feedback attenuates the oncogenic activity of YAP in pancreatic cancer
Sun, T., Mao, W., Peng, H., Ma, L., Liu, H., Mai, J., & Jiao, L. (2021) · International Journal of Biological Sciences · doi:10.7150/ijbs.61795 · Cited by 18
“Unfortunately, KRAS has been proven to be difficult to target and the therapeutic strategy of directly blocking KRAS activity with small-molecule inhibitors has proven challenging [11].”
BackgroundTargeting Mutated KRAS Genes to Treat Solid Tumours
Krishnan, T., Roberts‐Thomson, R., Broadbridge, V. T., & Price, T. J. (2021) · Molecular Diagnosis & Therapy · doi:10.1007/s40291-021-00564-0 · Cited by 22
“Of these, the G12D mutation makes up 34%, G12V mutation 21% and G13 mutation 20% [22].”
BackgroundDiehl, J. N., Hibshman, P. S., Ozkan‐Dagliyan, I., Goodwin, C. M., Howard, S. V., Cox, A. D., & Der, C. J. (2022) · Advances in cancer research · doi:10.1016/bs.acr.2021.07.008 · Cited by 19
Self-citationLoss of MLL Induces Epigenetic Dysregulation of Rasgrf1 to Attenuate Kras-Driven Lung Tumorigenesis
Zhu, L.-Y., Yuan, J.-B., Zhang, L., He, C.-X., Lin, X., Xu, B., & Jin, G. (2022) · Cancer Research · doi:10.1158/0008-5472.can-22-1475 · Cited by 20
Chen, X., Tang, G.-X., Dai, J., Dai, L.-T., Wu, T.-Y., Li, W., Ou, T., Huang, Z., Tan, J., & Chen, S.-B. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c00094 · Cited by 18
Prediction of KRASG12C inhibitors using conjoint fingerprint and machine learning-based QSAR models
Srisongkram, T., Khamtang, P., & Weerapreeyakul, N. (2023) · Journal of Molecular Graphics and Modelling · doi:10.1016/j.jmgm.2023.108466 · Cited by 24
Targeting KRASG12V mutations with HLA class II-restricted TCR for the immunotherapy in solid tumors
Ai, Q., Li, F., Zou, S., Zhang, Z., Jin, Y., Jiang, L., Chen, H., Deng, X., Peng, C., Mou, N., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1161538 · Cited by 21
“Among them, KRAS G12V and G12D mutations are themost common, accounting for about 60% of pancreatic cancer, 20% of colorectal cancer, and 8% of non-small cell lung cancer (36, 37).”
BackgroundRecent advances in the development of inhibitors targeting KRAS-G12C and its related pathways
Zhao, D., Liu, Y., Yi, F., Zhao, X., & Lu, K. (2023) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2023.115698 · Cited by 21
Chemical Proteomics–Guided Discovery of Covalent Ligands for Cancer Proteins
Zhang, X., & Cravatt, B. F. (2024) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-061421-041946 · Cited by 21
Pharmacological Inhibition of Protein Lipidation
Ganesan, L., & Levental, I. (2015) · The Journal of Membrane Biology · doi:10.1007/s00232-015-9835-4 · Cited by 20
“Importantly, some of these lipidated disease targets (e.g., Hh) have no enzyme activity of their own, while the enzymatic activity of others (e.g., Ras) has proven intractable to pharmacological perturbations (Cox et al. 2014).”
BackgroundInfluentialSeeing is believing: Ras dimers observed in live cells
Philips, M. R., & Der, C. J. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1511805112 · Cited by 20
Self-citationKRAS mutation in secondary malignant histiocytosis arising from low grade follicular lymphoma
Choi, S. M., Andea, A. A., Wang, M., Behdad, A., Shao, L., Zhang, Y., Lu, X., Dittmann, D., Castro, J., Chen, Y.-H., et al. (2018) · Diagnostic Pathology · doi:10.1186/s13000-018-0758-0 · Cited by 21
Mutation-Specific and Common Phosphotyrosine Signatures of KRAS G12D and G13D Alleles
Tahir, R., Renuse, S., Udainiya, S., Madugundu, A. K., Cutler, J. A., Nirujogi, R. S., Na, C. H., Xu, Y., Wu, X., & Pandey, A. (2020) · Journal of Proteome Research · doi:10.1021/acs.jproteome.0c00587 · Cited by 22
“model system (25), our focused analysis of the tyrosine phosphorylated fraction of the”
BackgroundSingh, K., Pruski, M. A., Polireddy, K., Jones, N. C., Chen, Q., Yao, J., Dar, W. A., McAllister, F. M., Ju, C., Eltzschig, H. K., et al. (2019) · Oncogene · doi:10.1038/s41388-019-1031-z · Cited by 18
Query-guided protein–protein interaction inhibitor discovery
Celis, S., Hóbor, F., James, T., Bartlett, G. J., Ibarra, A. Á., Shoemark, D. K., Hegedüs, Z., Hetherington, K., Woolfson, D. N., Sessions, R. B., et al. (2021) · Chemical Science · doi:10.1039/d1sc00023c · Cited by 17
Dong, Y.-L., Vadla, G. P., Lu, J., Ahmad, V., Klein, T. J., Liu, L., Glazer, P. M., Xu, T., & Chabu, C. Y. (2021) · Communications Biology · doi:10.1038/s42003-021-01898-5 · Cited by 21
Ford, K. M., Panwala, R., Chen, D.-H., Portell, A. J., Palmer, N. D., & Mali, P. (2021) · Cell Systems · doi:10.1016/j.cels.2021.05.002 · Cited by 22
“Compounding this, RAS and MYC have proven challenging to drug via small molecules, due to their lack of a binding pocket and reliance on protein-protein interactions for signal transduction (Cox et al., 2014).”
BackgroundRahmani, F., Hashemzehi, M., Avan, A., Barneh, F., Asgharzadeh, F., Marjaneh, R. M., Soleimani, A., Parizadeh, M., Ferns, G. A., Mobarhan, M. G., et al. (2021) · Cellular Signalling · doi:10.1016/j.cellsig.2021.110069 · Cited by 18
Yang, Y., Shen, S., Sun, Y., Husain, H., Zhou, H., Lü, S., & Li, Z. (2022) · Translational Lung Cancer Research · doi:10.21037/tlcr-22-88 · Cited by 21
“The discovery of targeted therapies for patients with epidermal growth factor receptor (EGFR) mutation and anaplastic lymphoma kinase (ALK) or c-ros oncogene 1 (ROS1) rearrangements has been a breakthrough in the treatment history of NSCLC (5-9).”
BackgroundThe Next Generation of KRAS Targeting: Reasons for Excitement and Concern
Akhave, N. S., Biter, A. B., & Hong, D. S. (2022) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-22-0356 · Cited by 17
Choi, J., Shin, J. H., Kim, T. K., Kim, K., Kim, J.-Y., Jeon, E., Park, J., Han, Y. D., Kim, K., Sim, T., et al. (2024) · Cancer Letters · doi:10.1016/j.canlet.2024.216904 · Cited by 21
Dutta, D., Ray, P., De, A., Ghosh, A., Hazra, R. S., Ghosh, P., Banerjee, S., Díaz, F. J., Upadhyay, S. P., Quadir, M., et al. (2024) · PLoS ONE · doi:10.1371/journal.pone.0297749 · Cited by 17
“As a result, most PDAC growth, progression, and survival are addicted to mutant K-RAS [11].”
Discovery of INCB159020, an Orally Bioavailable KRAS G12D Inhibitor
Ye, Q., Shvartsbart, A., Li, Z., Gan, P., Policarpo, R. L., Qi, C., Roach, J. J., Zhu, W., McCammant, M. S., Hu, B., et al. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c02662 · Cited by 20
Attili, I., Corvaja, C., Aliaga, P. T., Signore, E. D., Spitaleri, G., Passaro, A., & de Marinis, F. (2025) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2025.102957 · Cited by 20
Taylor, R. D., Chandran, A., Kashiwazaki, G., Hashiya, K., Bando, T., Nagase, H., & Sugiyama, H. (2015) · Chemistry - A European Journal · doi:10.1002/chem.201501870 · Cited by 17
Miniaturized Real-Time PCR on a Q3 System for Rapid KRAS Genotyping
Guarnaccia, M., Iemmolo, R., Petralia, S., Sabrina Conoci, A., & Cavallaro, S. (2017) · Sensors · doi:10.3390/s17040831 · Cited by 17
Gaudreau, P.-O., Lee, J. J., Heymach, J. V., & Gibbons, D. L. (2020) · Clinical Lung Cancer · doi:10.1016/j.cllc.2020.02.019 · Cited by 17
Niitsu, Y., Sato, Y., Takanashi, K., Hayashi, T., Kubo-Birukawa, N., Shimizu, F., Fujitani, N., Shimoyama, R., Kukitsu, T., Kurata, W., et al. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2000361117 · Cited by 16
Alternative splicing reverses the cell-intrinsic and cell-extrinsic pro-oncogenic potentials of YAP1
Ben, C., Wu, X., Takahashi‐Kanemitsu, A., Knight, C. T., Hayashi, T., & Hatakeyama, M. (2020) · Journal of Biological Chemistry · doi:10.1074/jbc.ra120.013820 · Cited by 19
“KRAS is most frequently mutated in pancreatic and colorectal cancers (36).”
BackgroundSugito, N., Heishima, K., & Akao, Y. (2022) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2022.09.001 · Cited by 17
“INTRODUCTION Rat sarcoma virus (RAS) mutations are genetic events that have been detected in approximately 30% of all human cancers, with the specific RAS isoform generally differing according to the cancer type.(1) Mutations in Kirsten rat sarcoma virus (KRAS) account for approximately 85% of all RASmutations.”
BackgroundTargeting Asparagine Synthetase in Tumorgenicity Using Patient-Derived Tumor-Initiating Cells
Nishikawa, G., Kawada, K., Hanada, K., Maekawa, H., Itatani, Y., Miyoshi, H., Taketo, M. M., & Obama, K. (2022) · Cells · doi:10.3390/cells11203273 · Cited by 20
“RAS mutation-induced metabolic reprogramming affects nutrient intake, glucose metabolism, and glutamine metabolism [4,13].”
BackgroundNi, Q., Zhu, B., Ji, Y., Zheng, Q., Liang, X., Ma, N., Jiang, H., Zhang, F., Shang, Y., Wang, Y., et al. (2022) · Advanced Science · doi:10.1002/advs.202202448 · Cited by 18
Mozammel, N., Amini, M. A., Baradaran, B., Mahdavi, S. Z. B., Hosseini, S. S., & Mokhtarzadeh, A. (2022) · Pathology - Research and Practice · doi:10.1016/j.prp.2022.154290 · Cited by 19
Frost, M. G., Jensen, K. J., Gotfredsen, D. R., Sørensen, A. M. S., Ankarfeldt, M. Z., Louie, K. S., Sroczynski, N., Jakobsen, E. H., Andersen, J. L., Jimenez‐Solem, E., et al. (2022) · Lung Cancer · doi:10.1016/j.lungcan.2023.02.021 · Cited by 19
Potocki, P. M., Wójcik, P., Chmura, Ł., Goc, B., Fedewicz, M., Bielańska, Z., Swadźba, J., Konopka, K. W., Kwinta, Ł., & Wysocki, P. J. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24109073 · Cited by 20
“The difficulty has stemmed from many reasons, but mainly from the complexity of the RAS function: heterogeneity of its mutated isoforms, different modes of activation, presence of inter-pathway crosstalk, and feedback loops reactivating the blocked cascades [3,9].”
BackgroundMultiple medicinal chemistry strategies of targeting KRAS: State-of-the art and future directions
Shang, Y., Fu, S., Hao, Q., Ying, H., Wang, J., & Shen, T. (2024) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2023.107092 · Cited by 18
Meller, A., Kelly, D. G., Smith, L. G., & Bowman, G. R. (2024) · Protein Science · doi:10.1002/pro.4902 · Cited by 18
“Moreover, many proteins must be written off as undruggable because their structures lack pockets where an inhibitor has the potential to bind tightly enough to serve as a valuable drug (Borrel et al., 2015; Cox et al., 2014; Hopkins & Groom, 2002).”
BackgroundMuteeb, G., Khafaga, D. S. R., El-Morsy, M. T., Farhan, M., Aatif, M., & Hosney, M. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e37217 · Cited by 17
“In breast cancer, elevated expression and activation of Ras have been associated with increased aggressiveness of tumors, suggesting its potential as a prognostic indicator for breast cancer progression [73].”
BackgroundVyse, S., Howitt, A., & Huang, P. H. (2017) · Journal of Molecular Biology · doi:10.1016/j.jmb.2017.04.018 · Cited by 17
“A prime example of this is the exhaustive search using both RNA interference (RNAi) and chemical libraries for vulnerabilities in cancers with activating mutations in RAS, an oncogene which has proved extremely difficult to target directly [40, 41].”
Transcribing malignancy: transcription-associated genomic instability in cancer
Boulianne, B., & Feldhahn, N. (2017) · Oncogene · doi:10.1038/onc.2017.402 · Cited by 18
Isoform specific gene expression analysis of KRAS in the prognosis of lung adenocarcinoma patients
Yang, I. S., & Kim, S. (2018) · BMC Bioinformatics · doi:10.1186/s12859-018-2011-y · Cited by 17
“As a result of their distinct genetic structures, their biological characteristics, such as plasma membrane binding, have been shown to be different [1, 13].”
BackgroundBET inhibition is an effective approach against KRAS-driven PDAC and NSCLC
Jauset, T., Massó-Vallés, D., Martínez-Martín, S., Beaulieu, M.-È., Foradada, L., Fiorentino, F. P., Yokota, J., Haendler, B., Siegel, S., Whitfield, J. R., et al. (2018) · Oncotarget · doi:10.18632/oncotarget.24648 · Cited by 20
“Indeed, targeting KRAS has proven challenging at multiple levels and different strategies have been explored: inhibiting KRAS translation by interfering with its messenger RNA, impairing KRAS processing using farnesyltransferase inhibitors, directly targeting the KRAS protein by peptide inhibitors or instructing the i…”
BackgroundKatt, W. P., Blobel, N. J., Komarova, S. V., Antonyak, M. A., Nakano, I., & Cerione, R. A. (2018) · Oncotarget · doi:10.18632/oncotarget.26193 · Cited by 17
Ras Downstream Effector GGCT Alleviates Oncogenic Stress
He, Z., Wang, S., Shao, Y., Zhang, J., Wu, X., Chen, Y., Hu, J., Zhang, F., & Liu, X. (2019) · iScience · doi:10.1016/j.isci.2019.07.036 · Cited by 17
Thabet, N. A., El-Guendy, N., Mohamed, M. M., & Shouman, S. A. (2019) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2019.114773 · Cited by 17
Prognostic implications of RAS alterations in diverse malignancies and impact of targeted therapies
Kato, S., Okamura, R., Sicklick, J. K., Daniels, G. A., Hong, D. S., Goodman, A. M., Weihe, E., Lee, S., Khalid, N. K., Collier, R., et al. (2020) · International Journal of Cancer · doi:10.1002/ijc.32813 · Cited by 17
“sistent signaling in multiple downstream pathways, including the mitogen-activated protein kinase (MAPK) and the phosphoinositide 3-kinase (PI3K) pathways.(4) At the cellular level, oncogenic RAS alterations are also associated with increased anchorage-independent cell growth and implicated in cancer initiation and ag…”
BackgroundGanaie, A. A., Siddique, H. R., SHEIKH, I. A., Parray, A., Wang, L., Panyam, J., Villalta, P. W., Deng, Y., Konety, B. R., & Saleem, M. (2020) · Molecular Carcinogenesis · doi:10.1002/mc.23200 · Cited by 18
“29‐32 The major stumbling block in the management of KRAS‐driven cancers is the nonresponsiveness to conventional therapies.(32) This makes the development of anti‐RAS therapies as a major health priority.”
BackgroundDual inhibition of VEGF and PARP suppresses KRAS-mutant colorectal cancer
Zhong, L., Wang, R., Wang, Y., Peng, S., Ma, Y., Ding, S., Yang, H., Chen, S., Luo, X., & Wang, W. (2020) · Neoplasia · doi:10.1016/j.neo.2020.06.001 · Cited by 21
Tumors driven by RAS signaling harbor a natural vulnerability to oncolytic virus M1
Cai, J., Lin, K., Cai, W., Lin, Y., Liu, X., Guo, L., Zhang, J., Xu, W., Lin, Z., Wong, C.-W., et al. (2020) · Molecular Oncology · doi:10.1002/1878-0261.12820 · Cited by 20
Discovery of a dual Ras and ARF6 inhibitor from a GPCR endocytosis screen
Giubilaro, J., Schuetz, D. A., Stępniewski, T. M., Namkung, Y., Khoury, E., Lara‐Márquez, M., Campbell, S. L., Beautrait, A., Armando, S., Radresa, O., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-24968-y · Cited by 18
Targeting KRAS in NSCLC: Old Failures and New Options for “Non-G12c” Patients
Jacobs, F., Cani, M., Malapelle, U., Novello, S., Napoli, V. M., & Bironzo, P. (2021) · Cancers · doi:10.3390/cancers13246332 · Cited by 19
“Nevertheless, RAS proteins have another membrane targeting element, consisting of a polybasic amino acid tract (K-Ras4B) or cysteine residues that are reversibly acylated by palmitate fatty acid [2,9].”
BackgroundWong, P. S. H., Akrami, A., Houk, B. E., Vuu, I., & James, C. A. (2022) · Bioanalysis · doi:10.4155/bio-2022-0173 · Cited by 18
Probing the druggability of membrane-bound Rab5 by molecular dynamics simulations
Edler, E., & Stein, M. (2017) · Journal of Enzyme Inhibition and Medicinal Chemistry · doi:10.1080/14756366.2016.1260564 · Cited by 18
Park, M., Xu, X., Min, W., Sugiman‐Marangos, S. N., Beilhartz, G. L., Adams, J., Sidhu, S. S., Grunebaum, E., & Melnyk, R. A. (2018) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.8b00735 · Cited by 16
Rožanc, J., Sakellaropoulos, T., Antoranz, A., Guttà, C., Podder, B., Vetma, V., Rufo, N., Agostinis, P., Pliaka, V., Sauter, T., et al. (2018) · Cell Death and Differentiation · doi:10.1038/s41418-018-0210-8 · Cited by 17
Rittler, D., Baranyi, M., Molnár, E., Garay, T., Jalsovszky, I., Varga, I. K., Hegedüs, L., Aigner, C., Tóvári, J., Tímár, J., et al. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20194917 · Cited by 19
“Malignant melanoma is an aggressive tumor, and there are still patient groups without effective therapy; therefore, novel strategies are warranted to increase the survival of advanced melanoma patients [3,6,7].”
BackgroundERF deletion rescues RAS deficiency in mouse embryonic stem cells
Mayor‐Ruiz, C., Olbrich, T., Drosten, M., Lecona, E., Vega-Sendino, M., Ortega, S., Domínguez, O., Barbacid, M., Ruiz, S., & Fernández-Capetillo, Ó. (2018) · Genes & Development · doi:10.1101/gad.310086.117 · Cited by 17
“Given that RAS structural properties are unfavorable for the development of small molecule inhibitors (Cox et al. 2014), current therapies are oriented to target downstream effectors of RAS, such as RAF or MEK.”
BackgroundOsumi, H., Takashima, A., Ooki, A., Yoshinari, Y., Wakatsuki, T., Hirano, H., Nakayama, I., Okita, N., Sawada, R., Ouchi, K., et al. (2023) · Translational Oncology · doi:10.1016/j.tranon.2023.101718 · Cited by 16
“As guanosine-5′-triphosphate (GTP) ase activity is reduced, the RAS mutant (MT) protein remains in the active form and bound to guanosine triphosphate; the activated state of RAS MT protein is maintained for constant downstream signaling, making EGFR inhibitors ineffective [5].”
BackgroundZhang, Y., Larraufie, M.-H., Musavi, L., Akkiraju, H., Brown, L. M., & Stockwell, B. R. (2018) · Biochemistry · doi:10.1021/acs.biochem.7b01113 · Cited by 16
Zhou, Y., Tao, Q., Luo, C., Chen, J., Chen, G., & Sun, J. (2025) · Cancer Science · doi:10.1111/cas.70057 · Cited by 20
Discovery of Carbodiimide Warheads to Selectively and Covalently Target Aspartic Acid in KRASG12D
Sirocchi, L. S., Scharnweber, M., Oberndorfer, S., Siszler, G., Żak, K. M., Rumpel, K., Neumüller, R. A., & Wilding, B. (2025) · Journal of the American Chemical Society · doi:10.1021/jacs.5c03562 · Cited by 18
Masuzawa, R., Takahashi, K., Takano, K., Nishino, I., Sakai, T., & Endo, T. (2021) · The Journal of Biochemistry · doi:10.1093/jb/mvab116 · Cited by 16
Markov State Models Reconcile Conformational Plasticity of GTPase with Its Substrate Binding Event
Dandekar, B. R., Ahalawat, N., Sinha, S., & Mondal, J. (2023) · JACS Au · doi:10.1021/jacsau.3c00151 · Cited by 17
Alinejad, T., Modarressi, S., Sadri, Z., Zuo, H., & Chen, C. S. (2023) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-023-04747-6 · Cited by 19
Methylation of KRAS by SETD7 promotes KRAS degradation in non-small cell lung cancer
Chiang, C.-Y., Fan, S., Zheng, H., Guo, W., Zheng, Z., Sun, Y., Zhong, C., Zeng, J., Li, S., Zhang, M., et al. (2023) · Cell Reports · doi:10.1016/j.celrep.2023.113003 · Cited by 16
Hou, Q., Jiang, W., Li, W., Huang, C., Yang, K., Chen, X., Huang, M., Shu, C., Luo, G., Sun, H., et al. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c00992 · Cited by 14
Insights into the structure and function of the RNA ligase RtcB
Moncan, M., Rakhsh-Khorshid, H., Eriksson, L. A., Afshin Samali, A., & Gorman, A. M. (2023) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-023-05001-5 · Cited by 16
E3MPH16: An efficient endosomolytic peptide for intracellular protein delivery
Kawaguchi, Y., Kawamura, Y., Hirose, H., Kiyokawa, M., Hirate, M., Hirata, T., Higuchi, Y., & Futaki, S. (2024) · Journal of Controlled Release · doi:10.1016/j.jconrel.2024.01.067 · Cited by 18
Ionizable lipid nanoparticles for RAS protease delivery to inhibit cancer cell proliferation
Atsavapranee, E., Haley, R. M., Billingsley, M. M., Chan, A., Ruan, B., Figueroa‐Espada, C. G., Gong, N., Mukalel, A. J., Bryan, P. N., & Mitchell, M. J. (2024) · Journal of Controlled Release · doi:10.1016/j.jconrel.2024.05.015 · Cited by 16
“This active RAS has no available sites for small molecule drugs to bind, which is the conventional approach to target intracellular proteins [4].”
BackgroundPharmacological strategies to target oncogenic KRAS signaling in pancreatic cancer
Chuang, H.-C., Huang, P.-H., Kulp, S. K., & Chen, C. (2017) · Pharmacological Research · doi:10.1016/j.phrs.2017.01.006 · Cited by 17
Hušková, H., Ardin, M., Weninger, A., Vargová, K., Ghamry-Barrin, S., Villar, S., Olivier, M., Stopka, T., Herceg, Z., Hollstein, M., et al. (2017) · Oncogene · doi:10.1038/onc.2017.215 · Cited by 16
“39 The Q61L and Q61R alterations, found in AA_2 and UVC_2, respectively, are among the most highly transforming mutations in this residue in NIH-3T3 cells.”
BackgroundCruz-Nova, P., Schnoor, M., Correa‐Basurto, J., Bello, M., Briseño-Díaz, P., Rojo‐Domínguez, A., Ortíz-Mendoza, C. M., Guerrero-Aguirre, J., García-Vázquez, F., Hernández‐Rivas, R., et al. (2018) · BMC Cancer · doi:10.1186/s12885-018-4968-3 · Cited by 18
Targeting Mutant KRAS for Anticancer Therapy
Chen, F., Alphonse, M. P., Liu, Y., & Liu, Q. (2019) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026619666190902151307 · Cited by 15
Patterning of Oncogenic Ras Clustering in Live Cells Using Vertically Aligned Nanostructure Arrays
Mu, H., Zeng, Y., Zhuang, Y., Gao, W., Zhou, Y., Rajalingam, K., & Zhao, W. (2022) · Nano Letters · doi:10.1021/acs.nanolett.1c03886 · Cited by 15
T cells discriminate between groups C1 and C2 HLA-C
Sim, M. J. W., Stotz, Z., Lu, J., Brennan, P., Long, E. O., & Sun, P. D. (2022) · eLife · doi:10.7554/elife.75670 · Cited by 16
Colorectal Cancer Modeling with Organoids: Discriminating between Oncogenic RAS and BRAF Variants
Post, J. B., Roodhart, J. M. L., & Snippert, H. J. G. (2020) · Trends in cancer · doi:10.1016/j.trecan.2019.12.005 · Cited by 18
Stubbs, C. K., Biancucci, M., Vidimar, V., & Satchell, K. J. F. (2021) · Scientific Reports · doi:10.1038/s41598-021-97422-0 · Cited by 16
“RAS mutations are highly enriched specifically in three of the four most lethal cancers in the United States, including pancreatic adenocarcinoma (98%), colorectal adenocarcinoma (52%), and lung adenocarcinoma (32%) (1, 6).”
BackgroundInfluentialShai, A., Galouk, E., Miari, R., Tareef, H., Sammar, M., Zeidan, M., Rayan, A., & Falah, M. (2022) · Oncology Letters · doi:10.3892/ol.2022.13250 · Cited by 15
“Such mutations have been implicated in the pathogenesis of numerous cancers, including approximately 97% of pancreatic ductal adenocarcinoma, 52% of colorectal adenocarcinomas, 32% of lung adenocarcinomas (1,3,4), and lower percentages of other cancers (5,6).”
BackgroundOyedele, A.-Q. K., Ogunlana, A. T., Boyenle, I. D., Ibrahim, N. O., Gbadebo, I. O., Owolabi, N., Ashiru, M. A., Francis, A. C., Eyinade, O., & Adelusi, T. I. (2022) · Molecular Diversity · doi:10.1007/s11030-022-10534-1 · Cited by 18
Ras superfamily GTPase activating proteins in cancer: Potential therapeutic targets?
Xiao, H., Wang, G., Zhao, M., Wen, S., Ouyang, L., & Sun, Q. (2023) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2023.115104 · Cited by 20
Shetu, S. A., James, N., Rivera, G., & Bandyopadhyay, D. (2023) · Current Issues in Molecular Biology · doi:10.3390/cimb45030124 · Cited by 16
“Deltarasin Recent research revealed that Deltarasin (Table 1) inhibits Phosphodiesterase-δ (PDEδ) interaction with the hydrophobic pocket of PDEδ by downregulating the RAS/RAF signaling pathway, which in turn inhibits KRAS- associated pancreatic ductal cancer (PDAC) [43,44].”
BackgroundDe, S. K. (2023) · Current Medicinal Chemistry · doi:10.2174/0929867330666230330122000 · Cited by 17
Digestive system deep infiltrating endometriosis: What do we know
Yin, W., Li, X., Liu, P., Li, Y., Liu, J., Yu, S., & Tai, S. (2023) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.17921 · Cited by 20
“152 These CAMs also promote fibrosis in lesioned tissue.”
BackgroundLi, M., Dai, L.-T., Gao, Z.-Y., Yan, J.-T., Xu, S., Tan, J., Huang, Z., Chen, S.-B., & Chen, X. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c01773 · Cited by 17
Advances and Challenges in RAS Signaling Targeted Therapy in Leukemia
Chen, Y., Yin, Z., Westover, K. D., Zhou, Z., & Shu, L. (2024) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-24-0504 · Cited by 18
“RAS’s picomolar affinity for GTP and the challenge of designing small molecules capable of restoring mutant RAS’s defective GTPase activity have thwarted the successful development of direct inhibitors of oncogenic RAS (118).”
InfluentialCholesterol metabolism in pancreatic cancer and associated therapeutic strategies
Daya, T., Breytenbach, A., Gu, L., & Kaur, M. (2024) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2024.159578 · Cited by 21
Li, A., Li, S., Wang, P. G., Dang, C., Fan, X. M., Chen, M., Liu, D., Li, F., Liu, H., Zhang, W., et al. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c02939 · Cited by 19
Metadata
- Authors
- Cox, A. D., Fesik, S. W., Kimmelman, A. C., Luo, J., & Der, C. J.
- Affiliations
- University of North Carolina at Chapel Hill (US)
- Vanderbilt University (US)
- Dana-Farber Cancer Institute (US)
- National Cancer Institute (US)
- Corresponding author
- Der, Channing J.
- Venue
- Nature Reviews Drug Discovery
- Published
- 2014-10-17
- Volume
- 13
- Issue
- 11
- Pages
- 828-851
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- PMC
- PMC4355017
- OpenAlex
- W2081990599
- Cited by
- 1,997
- References
- 231
- Citations by year
- 2026: 134 · 2025: 160 · 2024: 194 · 2023: 185 · 2022: 213 · 2021: 237 · 2020: 204 · 2019: 166 · 2018: 156 · 2017: 166 · 2016: 106 · 2015: 71 · 2014: 2
- FWCI
- 10.90
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Reviews Drug Discovery (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institutes of Health (DP1OD006933, 5r01ca042978-30)
- U.S. Public Health Service (P50A095103-12)
- National Cancer Institute (P50CA127003, CA042978, R01CA175747, DP1CA174419, P50CA095103, CA175747, R01-CA042978, R21CA179193, RC2CA148375, CA179193, R01CA157490)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Tyrosine Phosphatases
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
- Keywords
- oncogenic Ras, RAS inhibitors, undruggable targets, synthetic lethality, RAS-mutant cancers, anticancer drug discovery, Ras signaling
- MeSH terms
- Animals, Antineoplastic Agents, Humans, Signal Transduction, Oncogene Proteins, ras Proteins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.